Inferra AI / Company / INSP
Inspire Medical Systems, Inc.
INSP · Health Care
Last earnings Aug 3, 2026
Key results
Generated revenuequarter
$217.1 million
Recent Business Highlights Generated revenue of $217.1 million in the second quarter of 2025, an 11% increase over the same quarter last year Achieved gross margin of 84.0% in the second quarter of 2025 Net loss was $3.6 million in the second quarter of 2025.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Achieved gross marginquarter
11%
Recent Business Highlights Generated revenue of $217.1 million in the second quarter of 2025, an 11% increase over the same quarter last year Achieved gross margin of 84.0% in the second quarter of 2025 Net loss was $3.6 million in the second quarter of 2025.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Adjusted net incomequarter
$13.3 million
Adjusted net income was $13.3 million Loss per share was $0.12 in the second quarter of 2025.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Adjusted EPSquarter
$0.45
Adjusted diluted earnings per share was $0.45 Initiated the full launch of the Inspire V neurostimulation system in the U.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Revenuequarter
$217.1 million
Second Quarter 2025 Financial Results Revenue was $217.1 million for the second quarter, an 11% increase from $195.9 million in the corresponding prior year period.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
revenue for the quarter was $207.2 million, an increase of 10% as compared to the prior year quarter.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Gross marginquarter
84.0%
Gross margin was 84.0% for the second quarter of 2025 compared to 84.8% in the second quarter of 2024.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Net incomequarter
$3.6 million
Net loss was $3.6 million for the second quarter of 2025 as compared to a net income of $9.8 million in the corresponding prior year period.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
The adjusted net income for the second quarter of 2025 was $0.45 per share.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
AI analysis
Q2 2025 · reported Aug 4, 2025
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
The quarter in charts
GAAP gross margin
Percent of revenue, as stated
EX-99 · Aug 4, 2025 Margin values as stated in the release.
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Generated revenue | $217.1 million | — | — |
| Achieved gross margin | 11% | — | 84.8% |
| Adjusted net income | $13.3 million | — | — |
| Adjusted EPS | $0.45 | — | — |
| Revenue | $217.1 million | — | — |
| Gross margin | 84.0% | — | 84.8% |
| Net income | $3.6 million | — | — |
Guidance · company-stated
Direction: Reiterated
“The company is maintaining its full year 2025 gross margin guidance of 84% to 86%.”
Classified from the release's primary full-year outlook statement.
Margin
Capital allocation
In addition, Adjusted EBITDA is not intended to be a measure of cash flow for management s discretionary use, as it does not reflect certain cash requirements such as tax payments, capital expenditures and certain other cash costs that may recur in the future.
Event summary
Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Reiterated
Margin: “The company is maintaining its full year 2025 gross margin guidance of 84% to 86%.”
Margin — Reiterated (“maintaining”)
“The company is maintaining its full year 2025 gross margin guidance of 84% to 86%.”
Classified from the release's primary full-year outlook statement.
Capital allocation
In addition, Adjusted EBITDA is not intended to be a measure of cash flow for management s discretionary use, as it does not reflect certain cash requirements such as tax payments, capital expenditures and certain other cash costs that may recur in the future.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Net income (loss) $ (3,592) $ 9,793 $ (600) $ (212) Interest and dividend income (4,486) (5,882) (9,552) (11,805) Interest expense 4 4 Income taxes 1,260 1,053 2,427 1,703 Depreciation and amortization 3,414 1,383 6,458 2,222 EBITDA (3,400) 6,347 (1,263) (8,092) Stock-based compensation expense (4) 41,724 32,322 72,780 58,644 Legal fees 1,736 1,736 Other 4,046 4,046 Adjusted EBITDA $ 44,106 $ 38,669 $ 77,299 $ 50,552 (4) Total stock-based compensation expense.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Reconciliation of GAAP Net Income Margin and Non-GAAP Adjusted EBITDA Margin Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Net income margin (5) (2) % 5 % % % Interest and dividend income (2) % (3) % (2) % (3) % Interest expense % % % % Income taxes 1 % 1 % 1 % % Depreciation and amortization 2 % 1 % 2 % 1 % Stock-based compensation expense (4) 18 % 16 % 16 % 16 % Legal fees 1 % % % % Other 2 % % 1 % % Adjusted EBITDA margin (6) 20 % 20 % 18 % 14 % (4) Total stock-based compensation expense.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
or foreign regulatory actions affecting us or the healthcare industry generally; risks related to our debt and capital structure; our ability to establish and maintain intellectual property protection for our Inspire therapy and system or avoid claims of infringement; tax risks; risks that we may be deemed an investment company under the Investment Company Act of 1940; regulatory risks; the volatility of the trading price of our common stock; and our expectations about market trends.
SEC original ↗Inspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 4, 2025
treasury debt securities 105,904 15 ( 37 ) 105,882 Short-term investments $ 192,958 $ 58 $ ( 93 ) $ 192,923 Long-Term: Corporate debt securities $ 39,471 $ 1 $ ( 101 ) $ 39,371 Asset-backed securities 3,116 1 ( 3 ) 3,114 U.
SEC original ↗Inspire Medical Systems, Inc. — 10-Q Quarterly report10-QAug 3, 2026
treasury debt securities 52,343 ( 348 ) 51,995 Long-term investments $ 94,930 $ 2 $ ( 452 ) $ 94,480 December 31, 2025 Amortized Unrealized Gross Aggregate Cost Gains Losses Fair Value Short-Term: Commercial paper $ 22,103 $ 25 $ $ 22,128 Corporate debt securities 57,694 134 57,828 U.
SEC original ↗Inspire Medical Systems, Inc. — 10-Q Quarterly report10-QAug 3, 2026
Strategy & priorities
(NYSE INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2025.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
We remain steadfast in our commitment to serving the many patients who struggle with untreated moderate to severe OSA, delivering strong patient outcomes and executing on our strategy to drive profitable growth and value creation for all stakeholders.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
This increase primarily reflected ongoing investments in the expansion of the U.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
The net loss includes a $4.0 million non-cash impairment of a strategic investment.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Risks & headwinds
Importantly, we believe the operational headwinds are temporary, and actions are underway to address them, continued Mr.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Operating expenses also included an additional one-time charge of $11.2 million of accelerated stock-based compensation expense for employees who are retirement eligible in accordance with changes to the Inspire incentive award plan upon the employee s death, disability, or retirement, and finally, $1.7 million in certain litigation-related legal expenses.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
We define Adjusted EBITDA as net income or loss, less interest income, plus interest expense, plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense, plus litigation-related legal expenses and other non-operating expenses less non-operating income.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
These forward-looking statements are based on management s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
SEC original ↗Inspire Medical Systems, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
These forward-looking statements are based on management s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
SEC original ↗Inspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 4, 2025
Such risks and uncertainties include, among others, estimates regarding the annual total addressable market for our Inspire therapy in the U.
SEC original ↗Inspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 4, 2025
Earnings deck slides
0 decks with slide viewInspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Inspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Inspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Inspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Inspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Inspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Inspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Inspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Inspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Inspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Inspire Medical Systems, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
33 documents- Q2 2026
- 8-KINSP
- 10-QINSP
- 8-KINSP
- 8-KINSP
- Q1 2026
- 8-KINSP
- 8-KINSP
- 8-KINSP
- 10-QINSP
- Q4 2025
- 10-KINSP
- 8-KINSP
- 8-KINSP
- EX-99INSP
- Q3 2025
- 8-KINSP
- 8-KINSP
- 10-QINSP
- 8-KINSP
- EX-99INSP
- Q2 2025
- 8-KINSP
- 8-KINSP
- 8-KINSP
- 10-QINSP
- Q1 2025
- 8-KINSP
- 8-KINSP
- 8-KINSP
- 10-QINSP
- Q4 2024
- 8-KINSP
- 10-KINSP
- 8-KINSP
- EX-99INSP
- Q3 2024
- 8-KINSP
- 8-KINSP
- 10-QINSP
- Q2 2024
- 10-QINSP
Earnings releases
9 documentsPresentations
11 documents
Transcripts
0 documentsNo transcripts for Inspire Medical Systems, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.